Erica L. Scheller
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Erica L. Scheller has a total of 409 co-authors. Here are the top co-authors by number of shared publications:
- Ormond A. MacDougald
Department of Molecular & Integrative Physiology, University of Michigan Medical School, Ann Arbor, Michigan, USA
16 shared publications - William Peter Cawthorn
University of Edinburgh
15 shared publications Becky R. Simon
Department of Molecular & Integrative Physiology, University of Michigan, Ann Arbor, MI 48105, USA
7 shared publicationsBrian S. Learman
Department of Molecular & Integrative Physiology, University of Michigan Medical School , Ann Arbor, MI , USA
7 shared publicationsClarissa S. Craft
Division of Bone and Mineral Diseases, Department of Internal Medicine, Washington University School of Medicine, Saint Louis, MO, 63110, USA
6 shared publicationsMadelyn R. Lorenz
Division of Bone and Mineral Diseases, Department of Internal Medicine, Washington University School of Medicine, Saint Louis, MO, 63110, USA
6 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by Springer Nature in Reviews in Endocrine and Metabolic Disorders
- p. 1-18
Regulation and implications of adipocyte lipolysis in musculoskeletal tissues
The musculoskeletal (MSK) system contains several unique adipose tissue depots with an emerging role in health and disease. This includes bone marrow adipose tissues (BMAT), intramuscular and epimuscular adipose tissues (IMAT/EMAT), and adipose tissues in joints and around tendons. Adipocytes within these depots are differentially sensitive to lipolytic stimuli which provides clues as to how, and when, local lipolysis participates in MSK health and global metabolism. This review covers known mechanisms regulating lipolysis in each of the MSK adipose depots while emphasizing commonalities and exploring unique features and potential consequences. For each depot, we evaluate its known basal and stimulated lipolytic responses, particularly in response to adrenergic stimuli, caloric restriction, and exercise. We further synthesize findings across fields including endocrinology, cancer biology, food science, and exercise metabolism. Overall, this review emphasizes the broad importance of lipolysis in MSK adipocytes across species and conditions and highlights translational challenges and opportunities. We also highlight ongoing and future work toward understanding how the mechanisms and consequences of lipolysis in adipocytes of the MSK system can contribute to our ability to promote and maintain health throughout the lifespan.
- 10 November 2026
- Published by Springer Nature in Reviews in Endocrine and Metabolic Disorders
- p. 1-18
Open AccessRegulation and implications of adipocyte lipolysis in musculoskeletal tissues
The musculoskeletal (MSK) system contains several unique adipose tissue depots with an emerging role in health and disease. This includes bone marrow adipose tissues (BMAT), intramuscular and epimuscular adipose tissues (IMAT/EMAT), and adipose tissues in joints and around tendons. Adipocytes within these depots are differentially sensitive to lipolytic stimuli which provides clues as to how, and when, local lipolysis participates in MSK health and global metabolism. This review covers known mechanisms regulating lipolysis in each of the MSK adipose depots while emphasizing commonalities and exploring unique features and potential consequences. For each depot, we evaluate its known basal and stimulated lipolytic responses, particularly in response to adrenergic stimuli, caloric restriction, and exercise. We further synthesize findings across fields including endocrinology, cancer biology, food science, and exercise metabolism. Overall, this review emphasizes the broad importance of lipolysis in MSK adipocytes across species and conditions and highlights translational challenges and opportunities. We also highlight ongoing and future work toward understanding how the mechanisms and consequences of lipolysis in adipocytes of the MSK system can contribute to our ability to promote and maintain health throughout the lifespan.
- 26 July 2026
- Published by Elsevier in Journal of Oral Biosciences
- Vol. 68 (5) , 100801
Pharmacological effects of PTH1R agonists on jaw bone fracture, periodontitis, orthodontic treatment and MRONJ: a view from dosing regimen settings
- 26 July 2026
- Published by Elsevier in Journal of Oral Biosciences
- Vol. 68 (5) , 100801
Pharmacological effects of PTH1R agonists on jaw bone fracture, periodontitis, orthodontic treatment and MRONJ: a view from dosing regimen settings
- Open Access
Wnt/β-catenin signaling regulates fibrotic atrophy of intra-articular adipose tissue in post-traumatic osteoarthritis
Synovial joints like the knee are home to adipose tissue depots whose anatomy and functions are closely intertwined with that of other intra-articular soft tissues such as synovium, underscoring the growing understanding that joints are multi-tissue organs. Traumatic joint injury and the onset of osteoarthritis (OA) dramatically remodel the intra-articular adipose niche, marked by infiltration of fibrotic tissue postulated to underpin OA-associated joint stiffness and pain, yet we know very little about the disease-associated dynamics of joint adipose remodeling nor the mechanisms driving these phenomena. Here, we employed 2D histomorphometry and spatial transcriptomics, alongside 3D osmium tetroxide-enhanced micro-computed tomography to comprehensively define the spatiotemporal, structural, and transcriptional rewiring of joint adipose tissue in a non-invasive mouse model of post-traumatic osteoarthritis (PTOA). These revealed marked loss of intra-articular adiposity accompanied by expansion of fibroblast-rich, collagen-dense tissue with pro-fibrotic hallmarks and Wnt/β-catenin-enriched gene programs. Joint adipose exhibited a distinct transcriptional signature compared to subcutaneous white adipose tissue, pointing to unique, depot-specific functions. Stromal cells isolated from PTOA joints had heightened baseline expression of fibrotic and Wnt pathway genes and exhibited impaired de novo adipogenesis, in contrast to cells derived from healthy joints. In accordance with the destabilized biomechanics of PTOA joints, in vitro modeling demonstrated that prolonged, injurious loading and perturbed Wnt/β-catenin signaling were convergent anti-adipogenic cues that suppressed lipid droplet formation and adipogenic gene induction, while promoting markers of fibrosis in joint-derived stromal cells. Complementary gain-of-function studies using ex vivo joint adipose explants and in vivo joint injections demonstrated that chronic Wnt/β-catenin activation, as seen in OA joints, is sufficient to diminish the intra-articular adipogenic program and shift adipose to a more fibrotic phenotype, independent of joint injury. Collectively, these findings establish a multi-modal framework for quantifying joint adipose atrophy and implicate aberrant Wnt/β-catenin signaling and pathological mechanical loading as key factors impairing de novo adipogenesis and driving fibrotic remodeling of intra-articular adipose tissue in PTOA.
Open AccessWnt/β-catenin signaling regulates fibrotic atrophy of intra-articular adipose tissue in post-traumatic osteoarthritis
Synovial joints like the knee are home to adipose tissue depots whose anatomy and functions are closely intertwined with that of other intra-articular soft tissues such as synovium, underscoring the growing understanding that joints are multi-tissue organs. Traumatic joint injury and the onset of osteoarthritis (OA) dramatically remodel the intra-articular adipose niche, marked by infiltration of fibrotic tissue postulated to underpin OA-associated joint stiffness and pain, yet we know very little about the disease-associated dynamics of joint adipose remodeling nor the mechanisms driving these phenomena. Here, we employed 2D histomorphometry and spatial transcriptomics, alongside 3D osmium tetroxide-enhanced micro-computed tomography to comprehensively define the spatiotemporal, structural, and transcriptional rewiring of joint adipose tissue in a non-invasive mouse model of post-traumatic osteoarthritis (PTOA). These revealed marked loss of intra-articular adiposity accompanied by expansion of fibroblast-rich, collagen-dense tissue with pro-fibrotic hallmarks and Wnt/β-catenin-enriched gene programs. Joint adipose exhibited a distinct transcriptional signature compared to subcutaneous white adipose tissue, pointing to unique, depot-specific functions. Stromal cells isolated from PTOA joints had heightened baseline expression of fibrotic and Wnt pathway genes and exhibited impaired de novo adipogenesis, in contrast to cells derived from healthy joints. In accordance with the destabilized biomechanics of PTOA joints, in vitro modeling demonstrated that prolonged, injurious loading and perturbed Wnt/β-catenin signaling were convergent anti-adipogenic cues that suppressed lipid droplet formation and adipogenic gene induction, while promoting markers of fibrosis in joint-derived stromal cells. Complementary gain-of-function studies using ex vivo joint adipose explants and in vivo joint injections demonstrated that chronic Wnt/β-catenin activation, as seen in OA joints, is sufficient to diminish the intra-articular adipogenic program and shift adipose to a more fibrotic phenotype, independent of joint injury. Collectively, these findings establish a multi-modal framework for quantifying joint adipose atrophy and implicate aberrant Wnt/β-catenin signaling and pathological mechanical loading as key factors impairing de novo adipogenesis and driving fibrotic remodeling of intra-articular adipose tissue in PTOA.
- Open Access
- 2 May 2026
- Published by Wiley in The FASEB Journal
- Vol. 40 (9) , e71846
Quantification of SARM1 NADase Activity in Human Peripheral Blood Mononuclear Cells
SARM1 (sterile α and TIR motif‐containing protein‐1) is an NADase enzyme that serves as the central executioner of Wallerian axon degeneration. Given this, SARM1 is of high interest as a candidate therapeutic target, and SARM1 inhibitors are currently in clinical trials for treatment of neurodegeneration. Beyond neuroscience, emerging studies reveal that SARM1 may also drive aspects of bone fragility, liver pathology, adipose expansion, and insulin resistance in metabolic disease. However, we lack methods to quantify SARM1 activation in humans to better define patients at high risk of SARM1‐mediated tissue damage. Unlike neurons, peripheral blood mononuclear cells (PBMCs) represent an easily accessible population for clinical screening. While SARM1 gene expression has been identified in PBMCs, it is less known whether functional SARM1 NADase is present. We hypothesized that by pairing activators and inhibitors of SARM1 with analysis of downstream changes in cellular metabolites, we could identify and quantify both basal SARM1 activity and the SARM1 activation potential of human PBMCs. Our results reveal that SARM1 agonist pyrinuron, also known as Vacor, activates a dose‐dependent increase in cAPDR and the cADPR:ADPR ratio that is arrested when paired with SARM1 inhibitor DSRM‐3716. Changes in secondary metabolites including NAD+, NMN, NaMN, ATP, AMP, IMP, inosine, and succinyl adenosine were also characterized and used to generate a working model of PBMC SARM1 activation. Overall, these findings demonstrate that human PBMCs have detectable SARM1 activation potential and could be leveraged as a clinical readout of SARM1 expression and activity across diverse disease contexts.
- 2 May 2026
- Published by Wiley in The FASEB Journal
- Vol. 40 (9) , e71846
Open AccessQuantification of SARM1 NADase Activity in Human Peripheral Blood Mononuclear Cells
SARM1 (sterile α and TIR motif‐containing protein‐1) is an NADase enzyme that serves as the central executioner of Wallerian axon degeneration. Given this, SARM1 is of high interest as a candidate therapeutic target, and SARM1 inhibitors are currently in clinical trials for treatment of neurodegeneration. Beyond neuroscience, emerging studies reveal that SARM1 may also drive aspects of bone fragility, liver pathology, adipose expansion, and insulin resistance in metabolic disease. However, we lack methods to quantify SARM1 activation in humans to better define patients at high risk of SARM1‐mediated tissue damage. Unlike neurons, peripheral blood mononuclear cells (PBMCs) represent an easily accessible population for clinical screening. While SARM1 gene expression has been identified in PBMCs, it is less known whether functional SARM1 NADase is present. We hypothesized that by pairing activators and inhibitors of SARM1 with analysis of downstream changes in cellular metabolites, we could identify and quantify both basal SARM1 activity and the SARM1 activation potential of human PBMCs. Our results reveal that SARM1 agonist pyrinuron, also known as Vacor, activates a dose‐dependent increase in cAPDR and the cADPR:ADPR ratio that is arrested when paired with SARM1 inhibitor DSRM‐3716. Changes in secondary metabolites including NAD+, NMN, NaMN, ATP, AMP, IMP, inosine, and succinyl adenosine were also characterized and used to generate a working model of PBMC SARM1 activation. Overall, these findings demonstrate that human PBMCs have detectable SARM1 activation potential and could be leveraged as a clinical readout of SARM1 expression and activity across diverse disease contexts.
- 21 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 19 (934) , eaea2753
Activation of the NLRP3 inflammasome in osteoclasts is suppressed by a Tmem178-dependent mechanism that restricts Ca 2+ influx
Activation of the NLRP3 inflammasome can drive bone resorption by osteoclasts in various inflammatory conditions. Here, we identified Tmem178, a protein that restrains Ca 2+ fluxes by limiting SOCE activation, as an inhibitor of NLRP3 inflammasome activation and the bone-resorbing activity of osteoclasts. We found that NLRP3 abundance gradually decreased during osteoclastogenesis but was restored by treatment with the bacterial product LPS. LPS and the NLRP3 activator nigericin stimulated this inflammasome in macrophages, as expected, but not in osteoclasts or their lineage-committed precursors. This differential NLRP3 activation was due to Tmem178, a protein abundant in osteoclasts that suppressed NLRP3 inflammasome nucleation. Accordingly, NLRP3 inflammasome activation was robust in osteoclasts lacking Tmem178 or in wild-type osteoclasts exposed to high Ca 2+ concentrations. In vivo studies demonstrated that inflammasome formation was enhanced under conditions in which osteoclasts efficiently release Ca 2+ from bone and that deletion of Nlrp3 rescued the osteopenic phenotype characteristic of Tmem178 −/− mice. Thus, our results indicate that Tmem178 potently restricts Ca 2+ influx in osteoclasts, thereby suppressing NLRP3 inflammasome activation.
- 21 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 19 (934) , eaea2753
Activation of the NLRP3 inflammasome in osteoclasts is suppressed by a Tmem178-dependent mechanism that restricts Ca 2+ influx
Activation of the NLRP3 inflammasome can drive bone resorption by osteoclasts in various inflammatory conditions. Here, we identified Tmem178, a protein that restrains Ca 2+ fluxes by limiting SOCE activation, as an inhibitor of NLRP3 inflammasome activation and the bone-resorbing activity of osteoclasts. We found that NLRP3 abundance gradually decreased during osteoclastogenesis but was restored by treatment with the bacterial product LPS. LPS and the NLRP3 activator nigericin stimulated this inflammasome in macrophages, as expected, but not in osteoclasts or their lineage-committed precursors. This differential NLRP3 activation was due to Tmem178, a protein abundant in osteoclasts that suppressed NLRP3 inflammasome nucleation. Accordingly, NLRP3 inflammasome activation was robust in osteoclasts lacking Tmem178 or in wild-type osteoclasts exposed to high Ca 2+ concentrations. In vivo studies demonstrated that inflammasome formation was enhanced under conditions in which osteoclasts efficiently release Ca 2+ from bone and that deletion of Nlrp3 rescued the osteopenic phenotype characteristic of Tmem178 −/− mice. Thus, our results indicate that Tmem178 potently restricts Ca 2+ influx in osteoclasts, thereby suppressing NLRP3 inflammasome activation.
- Open Access
Spatial transcriptomics for gene discovery identifies Slc13a5 as a modulator of bone mechanoadaptation
Bone is a dynamic tissue that continuously adapts its structure in response to mechanical loading, an essential process for maintaining skeletal health. However, this adaptive capacity declines with aging, contributing to increased fragility and fracture risk. Developing therapeutic strategies that preserve or restore bone mechanoadaptation in patients with increased bone fragility requires identifying key molecular regulators of this process. We applied spatial transcriptomics (GeoMx, NanoString) to characterize gene expression changes induced by mechanical loading in the murine tibia, focusing on periosteal and bone compartments in regions under tension and compression. Spatial data were validated and cross-compared with previously published bulk RNA-seq and laser-capture microdissection datasets, identifying a set of 12 genes consistently regulated by loading across independent platforms and laboratories. As part of a functional analysis, we selected Slc13a5 , a citrate transporter implicated in bone mineralization and metabolism. Conditional deletion of Slc13a5 in osteolineage cells using Osteocalcin-Cre significantly increased the loading-induced mineralizing surface in tensile regions compared with Cre⁻ Slc13a5 fl/fl littermates. In addition, Slc13a5 cKO mice exhibited lower resorption around the neutral axis after loading compared to controls. Together, these findings identify Slc13a5 as a regulator of bone adaptation in regions experiencing low mechanical stimulation and suggest it as a potential therapeutic target for conditions characterized by impaired mechanoadaptive responses. This study highlights spatial transcriptomics as a powerful gene discovery framework for bone, enabling identification of novel targets to understand mechanisms and develop therapies. Graphical
Open AccessSpatial transcriptomics for gene discovery identifies Slc13a5 as a modulator of bone mechanoadaptation
Bone is a dynamic tissue that continuously adapts its structure in response to mechanical loading, an essential process for maintaining skeletal health. However, this adaptive capacity declines with aging, contributing to increased fragility and fracture risk. Developing therapeutic strategies that preserve or restore bone mechanoadaptation in patients with increased bone fragility requires identifying key molecular regulators of this process. We applied spatial transcriptomics (GeoMx, NanoString) to characterize gene expression changes induced by mechanical loading in the murine tibia, focusing on periosteal and bone compartments in regions under tension and compression. Spatial data were validated and cross-compared with previously published bulk RNA-seq and laser-capture microdissection datasets, identifying a set of 12 genes consistently regulated by loading across independent platforms and laboratories. As part of a functional analysis, we selected Slc13a5 , a citrate transporter implicated in bone mineralization and metabolism. Conditional deletion of Slc13a5 in osteolineage cells using Osteocalcin-Cre significantly increased the loading-induced mineralizing surface in tensile regions compared with Cre⁻ Slc13a5 fl/fl littermates. In addition, Slc13a5 cKO mice exhibited lower resorption around the neutral axis after loading compared to controls. Together, these findings identify Slc13a5 as a regulator of bone adaptation in regions experiencing low mechanical stimulation and suggest it as a potential therapeutic target for conditions characterized by impaired mechanoadaptive responses. This study highlights spatial transcriptomics as a powerful gene discovery framework for bone, enabling identification of novel targets to understand mechanisms and develop therapies. Graphical
- Open Access
- 8 January 2026
- Published by Springer Nature in Nature Metabolism
- Vol. 8 (1) , 96-115
A catecholamine-independent pathway controlling adaptive adipocyte lipolysis
Several adipose depots, including constitutive bone marrow adipose tissue, resist conventional lipolytic cues. However, under starvation, wasting or cachexia, the body eventually catabolizes stable adipocytes through unknown mechanisms. Here we developed a mouse model of brain-evoked depletion of all fat, including stable constitutive bone marrow adipose tissue, independent of food intake, to study this phenomenon. Genetic, surgical and chemical approaches demonstrated that catabolism of stable adipocytes required adipose triglyceride lipase-dependent lipolysis but was independent of local nerves, the sympathetic nervous system and catecholamines. Instead, concurrent hypoglycaemia and hypoinsulinaemia activated a potent catabolic state by suppressing lipid storage and increasing catecholamine-independent lipolysis via downregulation of cell-autonomous lipolytic inhibitors including G0s2. This was also sufficient to delipidate classical adipose depots and was recapitulated in tumour-associated cachexic mice. Overall, this defines unique adaptations of stable adipocytes to resist lipolysis in healthy states while isolating a potent catecholamine-independent neurosystemic pathway by which the body can rapidly catabolize all adipose tissues.
- 8 January 2026
- Published by Springer Nature in Nature Metabolism
- Vol. 8 (1) , 96-115
Open AccessA catecholamine-independent pathway controlling adaptive adipocyte lipolysis
Several adipose depots, including constitutive bone marrow adipose tissue, resist conventional lipolytic cues. However, under starvation, wasting or cachexia, the body eventually catabolizes stable adipocytes through unknown mechanisms. Here we developed a mouse model of brain-evoked depletion of all fat, including stable constitutive bone marrow adipose tissue, independent of food intake, to study this phenomenon. Genetic, surgical and chemical approaches demonstrated that catabolism of stable adipocytes required adipose triglyceride lipase-dependent lipolysis but was independent of local nerves, the sympathetic nervous system and catecholamines. Instead, concurrent hypoglycaemia and hypoinsulinaemia activated a potent catabolic state by suppressing lipid storage and increasing catecholamine-independent lipolysis via downregulation of cell-autonomous lipolytic inhibitors including G0s2. This was also sufficient to delipidate classical adipose depots and was recapitulated in tumour-associated cachexic mice. Overall, this defines unique adaptations of stable adipocytes to resist lipolysis in healthy states while isolating a potent catecholamine-independent neurosystemic pathway by which the body can rapidly catabolize all adipose tissues.
- 17 November 2025
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 41 (5) , 463-464
Countering bone loss and marrow fat expansion in the race to Mars
- 17 November 2025
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 41 (5) , 463-464
Countering bone loss and marrow fat expansion in the race to Mars
- Open Access
- 13 October 2025
- Published by Wiley in Aging Cell
- Vol. 24 (11) , e70225
Six Drivers of Aging Identified Among Genes Differentially Expressed With Age
Many studies have compared gene expression in young and old samples to gain insights on aging, the primary risk factor for most chronic diseases. However, these studies only identify associations without distinguishing drivers of aging from compensatory geroprotective responses or incidental downstream effects. Here, we introduce a workflow to characterize causal effects of differentially expressed genes on lifespan. First, we performed a meta‐analysis of 25 gene expression datasets comprising samples of various tissues from healthy, untreated adult mammals (humans, dogs, and rodents) at two distinct ages. Genes were ranked by the number of datasets in which they exhibited consistent differential expression with age. The top age‐upregulated genes were TMEM176A, EFEMP1, CP, and HLA‐A; the top age‐downregulated genes were CA4, SIAH, SPARC, and UQCR10. Second, the effects of the top ranked genes on lifespan were measured by applying post‐developmental RNA interference of the corresponding ortholog in Caenorhabditis elegans . Out of 10 age‐upregulated and 9 age‐downregulated genes that were tested, two age‐upregulated genes ( csp‐3 /CASP1 and spch‐2 /RSRC1) and four age‐downregulated genes ( C42C1.8 /DIRC2, ost‐1 /SPARC, fzy‐1 /CDC20, and cah‐3 /CA4) produced significant and reproducible lifespan extension. Notably, the data do not suggest that the direction of differential expression with age is predictive of the effect on lifespan. Our study provides novel insight into the relationship between differential gene expression and aging phenotypes, pilots an unbiased workflow that can be easily repeated and expanded, and pinpoints six genes with evolutionarily conserved, causal roles in the aging process for further study.
- 13 October 2025
- Published by Wiley in Aging Cell
- Vol. 24 (11) , e70225
Open AccessSix Drivers of Aging Identified Among Genes Differentially Expressed With Age
Many studies have compared gene expression in young and old samples to gain insights on aging, the primary risk factor for most chronic diseases. However, these studies only identify associations without distinguishing drivers of aging from compensatory geroprotective responses or incidental downstream effects. Here, we introduce a workflow to characterize causal effects of differentially expressed genes on lifespan. First, we performed a meta‐analysis of 25 gene expression datasets comprising samples of various tissues from healthy, untreated adult mammals (humans, dogs, and rodents) at two distinct ages. Genes were ranked by the number of datasets in which they exhibited consistent differential expression with age. The top age‐upregulated genes were TMEM176A, EFEMP1, CP, and HLA‐A; the top age‐downregulated genes were CA4, SIAH, SPARC, and UQCR10. Second, the effects of the top ranked genes on lifespan were measured by applying post‐developmental RNA interference of the corresponding ortholog in Caenorhabditis elegans . Out of 10 age‐upregulated and 9 age‐downregulated genes that were tested, two age‐upregulated genes ( csp‐3 /CASP1 and spch‐2 /RSRC1) and four age‐downregulated genes ( C42C1.8 /DIRC2, ost‐1 /SPARC, fzy‐1 /CDC20, and cah‐3 /CA4) produced significant and reproducible lifespan extension. Notably, the data do not suggest that the direction of differential expression with age is predictive of the effect on lifespan. Our study provides novel insight into the relationship between differential gene expression and aging phenotypes, pilots an unbiased workflow that can be easily repeated and expanded, and pinpoints six genes with evolutionarily conserved, causal roles in the aging process for further study.
- Open Access
Quantification of SARM1 activity in human peripheral blood mononuclear cells
SARM1 (sterile α and TIR motif-containing protein-1) is an NADase enzyme that has been identified as the central executioner of Wallerian axon degeneration. Given this, SARM1 is of high interest as a candidate therapeutic target and SARM1 inhibitors are currently in clinical trials for prevention and treatment of neurodegeneration. Beyond neuroscience, emerging studies reveal that SARM1 activation may also drive aspects of bone fragility, liver pathology, adipose tissue expansion, and insulin resistance in settings of metabolic disease. However, we lack methods to quantify SARM1 activation in humans using clinical isolates to better define patients at high risk of SARM1-mediated tissue damage, informing the future clinical application of SARM1 inhibitors. Unlike neurons, peripheral blood mononuclear cells (PBMCs) represent an easily accessible population of cells for clinical screening. We hypothesized that by pairing activators and inhibitors of SARM1 with analysis of downstream changes in cellular metabolites, we could quantify both the basal SARM1 activity and the SARM1 activation potential of human PBMCs. Our results reveal that SARM1 agonist pyrinuron, also known as Vacor, activates a dose-dependent increase in cAPDR and the cADPR:ADPR ratio that is arrested when paired with SARM1 inhibitor DSRM-3716. Various changes in secondary metabolites were also characterized and reported herein. Overall, these findings demonstrate that human PBMCs have detectable SARM1 activation potential and could be leveraged as a clinical readout of SARM1 expression and activity across diverse disease contexts.
Open AccessQuantification of SARM1 activity in human peripheral blood mononuclear cells
SARM1 (sterile α and TIR motif-containing protein-1) is an NADase enzyme that has been identified as the central executioner of Wallerian axon degeneration. Given this, SARM1 is of high interest as a candidate therapeutic target and SARM1 inhibitors are currently in clinical trials for prevention and treatment of neurodegeneration. Beyond neuroscience, emerging studies reveal that SARM1 activation may also drive aspects of bone fragility, liver pathology, adipose tissue expansion, and insulin resistance in settings of metabolic disease. However, we lack methods to quantify SARM1 activation in humans using clinical isolates to better define patients at high risk of SARM1-mediated tissue damage, informing the future clinical application of SARM1 inhibitors. Unlike neurons, peripheral blood mononuclear cells (PBMCs) represent an easily accessible population of cells for clinical screening. We hypothesized that by pairing activators and inhibitors of SARM1 with analysis of downstream changes in cellular metabolites, we could quantify both the basal SARM1 activity and the SARM1 activation potential of human PBMCs. Our results reveal that SARM1 agonist pyrinuron, also known as Vacor, activates a dose-dependent increase in cAPDR and the cADPR:ADPR ratio that is arrested when paired with SARM1 inhibitor DSRM-3716. Various changes in secondary metabolites were also characterized and reported herein. Overall, these findings demonstrate that human PBMCs have detectable SARM1 activation potential and could be leveraged as a clinical readout of SARM1 expression and activity across diverse disease contexts.